News

SAA is a rare disorder in which the bone marrow fails to make enough new blood cells. There are no approved therapies available for SAA patients who are

The patent application governs composition of matter for KP511, KemPharm’s prodrug of hydromorphone. KP511 is the second most advanced product candidate in KemPharm’s pain therapy portfolio, which includes

The trial is designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006. FX006 is designed to offer prolonged pain relief for the treatment

Nanobind is an inexpensive thermoplastic nanomaterial developed for high integrity DNA and RNA extraction. Its hierarchical structure of microscale folds topped by nanoscale wrinkles creates a high binding

The 2014 SWF Research Grants will support research conducted by two prominent investigators over two years. The grants are the largest awarded by the Sturge-Weber Foundation to date.

The merger, in combination with an expansive capital investment program, will create product development and production capabilities across 600,000ft² of manufacturing space. The combined scale and breadth of

The agreement includes cell line optimization, analytical development and manufacturing scale-up activities for Omni Bio’s leading AAT Fc fusion protein with the goal of providing cGMP product to

As part of the deal, REGENX granted AAVLife an exclusive worldwide license, with rights to sublicense, to deliver its NAV rAAVrh10 vector via non CNS routes to treat

The randomized, double masked, placebo controlled Phase II trial has enrolled a total of 142 treatment naive wet-AMD patients at more than 20 clinical sites in the US.